Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–8.
Council of the European Union. Council directive 97/43/EURATOM on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure. Off J Eur Communities. 1997;180:0022–7.
Buckley SE, Chittenden SJ, Saran FH, et al. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50:1518–24.
Turner JH. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Curr Pharm Des. 2009;15:966–82.
ICRP. Release of patients after therapy with unsealed radionuclides. ICRP publication 94. Ann ICRP. 2004;34(2).
IAEA. Release of patients after radionuclide therapy. Vienna: International Atomic Energy Agency; 2009.
Hoefnagel CA, Clarke SEM, Fischer M, et al. Radionuclide therapy practice and facilities in Europe. Eur J Nucl Med. 1999;26:277–82.
Harbert JC, Wells N. Radiation exposure to the families of radioactive patients. J Nucl Med. 1974;15:887–8.
Jacobson AP, Plato A, Toeroek D. Contamination of the home environment by patients treated with iodine-131: initial results. Am J Public Health. 1978;68:225–30.
Grisby PW, Siegel BA, Baker S, et al. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA. 2000;283:2272–4.
Willegagion J, Sapienza M, Ono C, et al. Outpatient therapy of thyroid cancer: a safe nuclear medicine procedure. Clin Nucl Med. 2011;36:440–5.
Gabriel S, Farman-Ara B, Bourrelly M, et al. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure. Nucl Med Commun. 2011;32:829–33.
Dauer LT, Zanzonico P, Tuttle RM, et al. The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi Power Facility: technical, radiologic and response perspectives. J Nucl Med. 2011;52:1423–32.
Australian Radiation Protection and Nuclear Safety Agency. Discharge of patients undergoing treatment with radioactive substances. Radiation protection series no. 4. ARPANSA; 2002.
Nuclear Regulatory Commission. Criteria for the release of individual administered radioactive materials, 10 CFR part 20 and 35: 62 FR 4120. Washington, DC: USNRC; 1997.
De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2011 [Epub ahead of print].
Turner JH, Martindale AA, Boucek J, et al. 131I-anti CD 20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a non-myeloablative dose regimen of chimeric rituximab radiolabelled in a hospital. Cancer Biother Radiopharm. 2003;18:513–24.
Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132:838–47.
Higashi T, Nishii R, Yamada S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683–9.
Pant GS, Sharma SK, Bal CS, et al. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131-I. Radiat Prot Dosimetry. 2006;118:22–7.
Goldsmith SJ. The real cost of theoretic risk avoidance: the need to challenge unsubstantiated concerns about 131I therapy. J Nucl Med. 2011;5:681–2.
Heads of the European Radiological Protection Competent Authorities. 131I therapy: patient release criteria. 30 June 2010.
IAEA Appendix I Safety Reports Series #63. IAEA; 2009.
Kinuya S. A nuclear power plant accident in Fukushima: what should we do? Ann Nucl Med. 2011. doi:10.1007/s12149-011-0555-2.
Higashi T, Kudo T, Kinuya S. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2011. doi:10.1007/s12149-011-0553-4.
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623–30.
Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934–40.
Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate for disseminated skeletal metastases. J Clin Oncol. 1989;17:1926–31.
Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose Samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer. 1991;27:1084–6.
Turner JH, Martindale AA, Sorby P, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784–95.
Sinzinger H, Palumbo B, Granegger S. Repeated low-dose Sm-153 EDTMP therapy using the Vienna protocol is effective in pain palliation and lesion regression. J Nucl Med. 2008;49(Suppl):369.
Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with new, high-energy radiopharmaceutical Rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21:2869–75.
Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40:89–104.
Lambert B, de Klerk JM. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun. 2006;27:223–9.
Bayouth JE, Macey DJ, Kasi LP, et al. Pharmacokinetics, dosimetry and toxicity of Holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995;36:730–7.
Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–66.
US Nuclear Regulatory Commission. Release of patients administered radioactive materials. Washington, DC: US Nuclear Regulatory Commission; 1997 (Regulatory Guide 8.39, 1997).
Rutar FJ, Augustine SC, Colcher D, et al. Outpatient treatment with 131I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001;42:907–15.
Rutar FJ, Augustine SC, Kaminski MS, et al. Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin’s lymphoma based on radiation doses to family members. Clin Lymphoma. 2001;2:164–72.
Calais PJ, Turner JH. Outpatient iodine-131-rituximab radioimmunotherapy of non-Hodgkin lymphoma: a study in safety. Clin Nucl Med. 2011 (in press).
Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10 year single-institution experience of 142 consecutive patients. Blood. 2011;117:45–52.
McQuillan AD, Macdonald WBG, Turner JH. Phase II study first-line Iodine-131-rituximab radioimmunotherapy of follicular non-Hodgkin lymphoma with Fluorine-18 FDG-PET-CT response end point. Blood 2011; (in press).
Lohri A, Forrer F, Campana B et al. Radioimmunotherapy (RIT) with 177Lutetium-DOTA-rituximab (177Lu-D-R): a phase I/II study in 30 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas. In: 50th ASH Annual Meeting and Exposition; 2008.
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy and survival. J Clin Oncol. 2008;26:2124–30.
Fitschen J, Knoop BO, Behrendt R et al. Äußere Strahlenexposition und effektive Halbwertszeit bei therpie mit Lu-177-Dota-Tate. Z Med Phys. 2011. doi:10.1016/j.zemedi.2011.05.001.
Brayshaw PA, Turner JH. Outpatient 177Lu-DOTA-tyr3-octreotate radiopeptide therapy of neuroendocrine tumours with personalized dosimetry and so to BED. Eur J Nucl Med Mol Imaging 2011 (under review).
Claringbold PG, Brayshaw PA, Price A, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302–11.
Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase I–II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumours. Acta Oncol. ESMO; 2011 (Abst).
Naji M, Zhao C, Welsh SJ, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13:769–75.
Grünwald F, Ezziddin S. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroblastoma tumors. Semin Nucl Med. 2010;40:153–63.
Sudbrock F, Boldt F, Kobe C, et al. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Nuklearmedizin. 2009;48:17–25.
Kwekkeboom DJ, de Herder WW, Casper HJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78–88.
Raoul J-L, Boucher E, Roland Y, et al. 131Iodine lipiodol therapy in hepatocellular carcinoma. Q J Nucl Med Mol Imaging. 2005;53:348–55.
Chua TC, Chu F, Butler P, et al. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer. 2010;116:4069–77.
Sundram F, Chau TCM, Onkhuudai P, et al. Preliminary results of transarterial Rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:250–7.
Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med. 2011;364:2055–8.
Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–601.
Morris MJ, Milowsky MI, Pandit-Taskar N et al. Phase 2 trial of 177Lutetium (177Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (177Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol. In: Proceedings of Asco Annual Meeting, part 1, vol 24, p. 18S; 2006.
Weill Medical College of Cornell University. 177Lu radiolabeled monoclonal antibody HuJ591 (177-Lu-J591) and ketoconazole in patients with prostate cancer. Clinical Trials.gov: NCT00859781; 2009.
Olafsen T, Ho DT, Lipman AA et al. Highly-specific small animal PET imaging of prostate specific membrane antigen (PSMA) xenografts by an engineered humanized antibody fragment (minibody). In: ASCO. http://www.wmicmeeting.org/2010/Abstracts.
Schroeder RPJ, Müller C, Reneman S, et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:1386–96.
Maddalena ME, Fox J, Chen J, et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med. 2009;50:2017–24.
Nock B, Nikolopoulou A, Chiotellis E, et al. [99mTc] Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med. 2003;30:247–58.
Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97–107.
Lam MGEH, Bosma TB, van Rijk PP, et al. 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging. 2009;36:1425–33.
Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429–35.
Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40:167–81.
Sharkey RM, Rossi EA, McBride WJ, et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med. 2010;40:190–203.
Brans B, Van Den Eynde F, Audenaert K, et al. Depression and anxiety during isolation and radionuclide therapy. Nucl Med Commun. 2003;24:881–6.
The World Association of Radionuclide & Molecular Therapy (WARMTH). http://www.warmolth.org.